^
Association details:
| Biomarker: | CLDN18.2 expression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | EO-3021 (Microtubule inhibitor, CLDN18.2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
Excerpt:
...- Select advanced or metastatic solid tumor that is likely to express CLDN18.2 such as gastric/GEJ, pancreatic and esophageal cancer...
Trial ID:
Source:
Title:
Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor
Excerpt:
...Subjects with locally advanced unresectable or metastatic malignant solid tumors confirmed by histology and/or cytology and CLDN 18.2 positive expression in the tumor tissue confirmed by the central laboratory: dose-escalation phase defined as IHC ≥ 1+ by central laboratory IHC assay; dose-expansion phase and extension cohort studies defined as CLDN18.2 expression in ≥ 40% of tumor cells, the IHC ≥ 2+); 4....
Trial ID:
Less C2 evidence
Source:
Title:
First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors.
Published date:
05/25/2023
Excerpt:
SYSA1801 shows promising early signs of efficacy with a well-tolerated safety profile in pts with CLDN18.2-expressing resistant/refractory solid tumors, especially GC.
DOI:
10.1200/JCO.2023.41.16_suppl.3016
Trial ID:
